Stay updated on SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page.

Latest updates to the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page
- Check7 days agoChange DetectedThe clinical trial page now presents the study record for CRS-207 with epacadostat, including its design, participant criteria, locations, outcome measures, and study documents. The record identifies the trial as terminated and no longer recruiting participants.SummaryDifference72%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check27 days agoChange DetectedA site-wide banner announces NIH website updates and says that “Super Intelligence” is replacing “Artificial Intelligence” terminology across NIH content during the transition.SummaryDifference1%

- Check34 days agoChange DetectedThe revision label in the footer changed from v3.7.1 to v3.7.2 on the access-denied page.SummaryDifference0.2%

- Check41 days agoChange DetectedThe site footer revision label changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the usual study record content and blocking access to the study details.SummaryDifference21%

Stay in the know with updates to SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page.